Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US
Executive Summary
Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its bioabsorbable Synergy drug-eluting stent. The company expects it will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease.
You may also be interested in...
Boston Sci Says It Will Be Careful About Resorbable Scaffold Investment
The company announced July 20 the start of its 30-patient, single-arm FAST study assessing its everolimus-eluting scaffold system, but executives says Boston Scientific will be closely considering whether the system warrants long-term investment, considering the promise of its Synergy stent.
Abbott Submits PMA For Absorb Bioresorbable Scaffold
The firm's FDA submission for the first-in-class bioresorbable vascular scaffold was completed in the second quarter, a spokesman said. That appears to be ahead of a prior estimate to submit by the end of 2015.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.